Polo-like Kinase 1 Inhibitors Demonstrate In Vitro and In Vivo Efficacy in Preclinical Models of Small Cell Lung CancerGuojing Zhang(University of Maryland, Baltimore), Taofeek K. Owonikoko(University of Maryland, Baltimore)CancersJanuary 28, 202510.3390/cancers17030446Cited by 2SaveCiteExport RISWatch citationsRelated PapersRandomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses|Journal of Thoracic Oncology|2019|146